Opioid Induced Constipation (OIC) Drugs-Asia Pacific Market Status and Trend Report 2013-2023
Report Summary
Opioid Induced Constipation (OIC) Drugs-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Opioid Induced Constipation (OIC) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Asia Pacific and Regional Market Size of Opioid Induced Constipation (OIC) Drugs 2013-2017, and development forecast 2018-2023
Main market players of Opioid Induced Constipation (OIC) Drugs in Asia Pacific, with company and product introduction, position in the Opioid Induced Constipation (OIC) Drugs market
Market status and development trend of Opioid Induced Constipation (OIC) Drugs by types and applications
Cost and profit status of Opioid Induced Constipation (OIC) Drugs, and marketing status
Market growth drivers and challenges
The report segments the Asia Pacific Opioid Induced Constipation (OIC) Drugs market as:
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
China
Japan
Korea
India
Southeast Asia
Australia
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Players Segment Analysis (Company and Product introduction, Opioid Induced Constipation (OIC) Drugs Sales Volume, Revenue, Price and Gross Margin):
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Valeant Pharmaceuticals International
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Opioid Induced Constipation (OIC) Drugs-Asia Pacific Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Opioid Induced Constipation (OIC) Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole Asia Pacific and Regional Market Size of Opioid Induced Constipation (OIC) Drugs 2013-2017, and development forecast 2018-2023
Main market players of Opioid Induced Constipation (OIC) Drugs in Asia Pacific, with company and product introduction, position in the Opioid Induced Constipation (OIC) Drugs market
Market status and development trend of Opioid Induced Constipation (OIC) Drugs by types and applications
Cost and profit status of Opioid Induced Constipation (OIC) Drugs, and marketing status
Market growth drivers and challenges
The report segments the Asia Pacific Opioid Induced Constipation (OIC) Drugs market as:
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
China
Japan
Korea
India
Southeast Asia
Australia
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Other
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific Opioid Induced Constipation (OIC) Drugs Market: Players Segment Analysis (Company and Product introduction, Opioid Induced Constipation (OIC) Drugs Sales Volume, Revenue, Price and Gross Margin):
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Valeant Pharmaceuticals International
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
1.1 Definition of Opioid Induced Constipation (OIC) Drugs in This Report
1.2 Commercial Types of Opioid Induced Constipation (OIC) Drugs
1.2.1 Lubiprostone
1.2.2 Methyl Naltrexone Bromide
1.2.3 Naldemedine
1.2.4 Alvimopan
1.2.5 Other
1.3 Downstream Application of Opioid Induced Constipation (OIC) Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Opioid Induced Constipation (OIC) Drugs
1.5 Market Status and Trend of Opioid Induced Constipation (OIC) Drugs 2013-2023
1.5.1 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Opioid Induced Constipation (OIC) Drugs Market Status and Trend 2013-2023
CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Opioid Induced Constipation (OIC) Drugs in Asia Pacific 2013-2017
2.2 Consumption Market of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.2.1 Consumption Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.2.2 Revenue of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.3 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.3.1 Market Analysis of Opioid Induced Constipation (OIC) Drugs in China 2013-2017
2.3.2 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Japan 2013-2017
2.3.3 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Korea 2013-2017
2.3.4 Market Analysis of Opioid Induced Constipation (OIC) Drugs in India 2013-2017
2.3.5 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Southeast Asia 2013-2017
2.3.6 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Australia 2013-2017
2.4 Market Development Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific 2018-2023
2.4.1 Market Development Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific 2018-2023
2.4.2 Market Development Forecast of Opioid Induced Constipation (OIC) Drugs by Regions 2018-2023
CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Asia Pacific Market Status by Types
3.1.1 Consumption Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Types
3.1.2 Revenue of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Types
3.2 Asia Pacific Market Status by Types in Major Countries
3.2.1 Market Status by Types in China
3.2.2 Market Status by Types in Japan
3.2.3 Market Status by Types in Korea
3.2.4 Market Status by Types in India
3.2.5 Market Status by Types in Southeast Asia
3.2.6 Market Status by Types in Australia
3.3 Market Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Types
CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Downstream Industry
4.2 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in China
4.2.2 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Japan
4.2.3 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Korea
4.2.4 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in India
4.2.5 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Southeast Asia
4.2.6 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Australia
4.3 Market Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
5.1 Asia Pacific Economy Situation and Trend Overview
5.2 Opioid Induced Constipation (OIC) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC
6.1 Sales Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Major Players
6.2 Revenue of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Major Players
6.3 Basic Information of Opioid Induced Constipation (OIC) Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Opioid Induced Constipation (OIC) Drugs Major Players
6.3.2 Employees and Revenue Level of Opioid Induced Constipation (OIC) Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 OPIOID INDUCED CONSTIPATION (OIC) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Ironwood Pharmaceuticals Inc
7.1.1 Company profile
7.1.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.1.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals Inc
7.2 Daiichi Sankyo Co Ltd
7.2.1 Company profile
7.2.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.2.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo Co Ltd
7.3 Pfizer
7.3.1 Company profile
7.3.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.3.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.4 Progenics Pharmaceuticals Inc
7.4.1 Company profile
7.4.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.4.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Progenics Pharmaceuticals Inc
7.5 Shionogi & Co., Ltd
7.5.1 Company profile
7.5.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.5.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Shionogi & Co., Ltd
7.6 Allergan Plc
7.6.1 Company profile
7.6.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.6.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Allergan Plc
7.7 Nektar Therapeutics
7.7.1 Company profile
7.7.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.7.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Nektar Therapeutics
7.8 Purdue Pharma
7.8.1 Company profile
7.8.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.8.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Purdue Pharma
7.9 S.L.A. Pharma AG
7.9.1 Company profile
7.9.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.9.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of S.L.A. Pharma AG
7.10 Mundipharma International Limited
7.10.1 Company profile
7.10.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.10.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Mundipharma International Limited
7.11 Ono Pharmaceutical Co., Ltd
7.11.1 Company profile
7.11.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.11.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Ono Pharmaceutical Co., Ltd
7.12 Takeda Pharmaceutical Company Limited
7.12.1 Company profile
7.12.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.12.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
7.13 Theravance Biopharma Inc
7.13.1 Company profile
7.13.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.13.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Theravance Biopharma Inc
7.14 Valeant Pharmaceuticals International
7.14.1 Company profile
7.14.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.14.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International
7.15 Cosmo Pharmaceuticals SA
7.15.1 Company profile
7.15.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.15.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Cosmo Pharmaceuticals SA
7.16 Daewoong Pharmaceutical
7.17 C.B. Fleet Company
7.18 Sucampo Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
8.1 Industry Chain of Opioid Induced Constipation (OIC) Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
9.1 Cost Structure Analysis of Opioid Induced Constipation (OIC) Drugs
9.2 Raw Materials Cost Analysis of Opioid Induced Constipation (OIC) Drugs
9.3 Labor Cost Analysis of Opioid Induced Constipation (OIC) Drugs
9.4 Manufacturing Expenses Analysis of Opioid Induced Constipation (OIC) Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Opioid Induced Constipation (OIC) Drugs in This Report
1.2 Commercial Types of Opioid Induced Constipation (OIC) Drugs
1.2.1 Lubiprostone
1.2.2 Methyl Naltrexone Bromide
1.2.3 Naldemedine
1.2.4 Alvimopan
1.2.5 Other
1.3 Downstream Application of Opioid Induced Constipation (OIC) Drugs
1.3.1 Hospital Pharmacies
1.3.2 Retail Pharmacies
1.3.3 Online Pharmacies
1.4 Development History of Opioid Induced Constipation (OIC) Drugs
1.5 Market Status and Trend of Opioid Induced Constipation (OIC) Drugs 2013-2023
1.5.1 Asia Pacific Opioid Induced Constipation (OIC) Drugs Market Status and Trend 2013-2023
1.5.2 Regional Opioid Induced Constipation (OIC) Drugs Market Status and Trend 2013-2023
CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Opioid Induced Constipation (OIC) Drugs in Asia Pacific 2013-2017
2.2 Consumption Market of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.2.1 Consumption Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.2.2 Revenue of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.3 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Regions
2.3.1 Market Analysis of Opioid Induced Constipation (OIC) Drugs in China 2013-2017
2.3.2 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Japan 2013-2017
2.3.3 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Korea 2013-2017
2.3.4 Market Analysis of Opioid Induced Constipation (OIC) Drugs in India 2013-2017
2.3.5 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Southeast Asia 2013-2017
2.3.6 Market Analysis of Opioid Induced Constipation (OIC) Drugs in Australia 2013-2017
2.4 Market Development Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific 2018-2023
2.4.1 Market Development Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific 2018-2023
2.4.2 Market Development Forecast of Opioid Induced Constipation (OIC) Drugs by Regions 2018-2023
CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES
3.1 Whole Asia Pacific Market Status by Types
3.1.1 Consumption Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Types
3.1.2 Revenue of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Types
3.2 Asia Pacific Market Status by Types in Major Countries
3.2.1 Market Status by Types in China
3.2.2 Market Status by Types in Japan
3.2.3 Market Status by Types in Korea
3.2.4 Market Status by Types in India
3.2.5 Market Status by Types in Southeast Asia
3.2.6 Market Status by Types in Australia
3.3 Market Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Types
CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Downstream Industry
4.2 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in China
4.2.2 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Japan
4.2.3 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Korea
4.2.4 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in India
4.2.5 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Southeast Asia
4.2.6 Demand Volume of Opioid Induced Constipation (OIC) Drugs by Downstream Industry in Australia
4.3 Market Forecast of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
5.1 Asia Pacific Economy Situation and Trend Overview
5.2 Opioid Induced Constipation (OIC) Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC
6.1 Sales Volume of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Major Players
6.2 Revenue of Opioid Induced Constipation (OIC) Drugs in Asia Pacific by Major Players
6.3 Basic Information of Opioid Induced Constipation (OIC) Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Opioid Induced Constipation (OIC) Drugs Major Players
6.3.2 Employees and Revenue Level of Opioid Induced Constipation (OIC) Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 OPIOID INDUCED CONSTIPATION (OIC) DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Ironwood Pharmaceuticals Inc
7.1.1 Company profile
7.1.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.1.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Ironwood Pharmaceuticals Inc
7.2 Daiichi Sankyo Co Ltd
7.2.1 Company profile
7.2.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.2.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo Co Ltd
7.3 Pfizer
7.3.1 Company profile
7.3.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.3.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.4 Progenics Pharmaceuticals Inc
7.4.1 Company profile
7.4.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.4.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Progenics Pharmaceuticals Inc
7.5 Shionogi & Co., Ltd
7.5.1 Company profile
7.5.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.5.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Shionogi & Co., Ltd
7.6 Allergan Plc
7.6.1 Company profile
7.6.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.6.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Allergan Plc
7.7 Nektar Therapeutics
7.7.1 Company profile
7.7.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.7.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Nektar Therapeutics
7.8 Purdue Pharma
7.8.1 Company profile
7.8.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.8.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Purdue Pharma
7.9 S.L.A. Pharma AG
7.9.1 Company profile
7.9.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.9.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of S.L.A. Pharma AG
7.10 Mundipharma International Limited
7.10.1 Company profile
7.10.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.10.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Mundipharma International Limited
7.11 Ono Pharmaceutical Co., Ltd
7.11.1 Company profile
7.11.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.11.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Ono Pharmaceutical Co., Ltd
7.12 Takeda Pharmaceutical Company Limited
7.12.1 Company profile
7.12.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.12.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Takeda Pharmaceutical Company Limited
7.13 Theravance Biopharma Inc
7.13.1 Company profile
7.13.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.13.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Theravance Biopharma Inc
7.14 Valeant Pharmaceuticals International
7.14.1 Company profile
7.14.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.14.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Valeant Pharmaceuticals International
7.15 Cosmo Pharmaceuticals SA
7.15.1 Company profile
7.15.2 Representative Opioid Induced Constipation (OIC) Drugs Product
7.15.3 Opioid Induced Constipation (OIC) Drugs Sales, Revenue, Price and Gross Margin of Cosmo Pharmaceuticals SA
7.16 Daewoong Pharmaceutical
7.17 C.B. Fleet Company
7.18 Sucampo Pharmaceuticals
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
8.1 Industry Chain of Opioid Induced Constipation (OIC) Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
9.1 Cost Structure Analysis of Opioid Induced Constipation (OIC) Drugs
9.2 Raw Materials Cost Analysis of Opioid Induced Constipation (OIC) Drugs
9.3 Labor Cost Analysis of Opioid Induced Constipation (OIC) Drugs
9.4 Manufacturing Expenses Analysis of Opioid Induced Constipation (OIC) Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF OPIOID INDUCED CONSTIPATION (OIC) DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
